滚动资讯
FierceBiotechCompass, Usona score FDA national priority vouchers amid Trump administration’s psychedelic pushBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 23, 2026FierceBiotech木马游戏——赫鲁斯上任两月后更换CEO，为科学委员会增添经验FierceBiotechAfter Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?BioWorldIn the clinic for April 24, 2026BioWorldOther news to note for April 24, 2026BioWorldRegulatory actions for April 24, 2026PLoS BiologyA cortico-subthalamic circuit rapidly engages and releases inhibition of specific movements depending on the environmental contextPLoS BiologyA mother’s gift: Provisioning of plastid-derived structures into eggs promotes invertebrate development and dispersalPLoS BiologyEmergent spatial structure in the gut microbiota is driven by bacterial growth and gut contractionsBioWorldSichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
Endpoints News 2025年12月8日

FDA未能在PDUFA审查截止日期前完成对Agios公司地中海贫血药物的评估。

FDA未能在PDUFA审查截止日期前完成对Agios公司地中海贫血药物的评估。

原文
暂时没有全文，请查看原始来源。